JW (Cayman) Therapeutics Co. Ltd
Research JW (Cayman) Therapeutics Co. Ltd (JNY) on Bullrun: market cap EUR 84.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJNY
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 84.96M
- Financial periodFY2025
- RevenueCNY 283.65M
- Revenue growth79.3%
- Net income-CNY 555.29M
- Free cash flow-CNY 78.46M
- Gross margin61.0%
Valuation Snapshot
latest market cap is EUR 84.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 283.65M | -CNY 555.29M | -CNY 78.46M | 61.0% | -1.34 | CNY 503.07M | CNY 262.56M | CNY 556.26M |
| FY2024 | CNY 158.22M | -CNY 590.62M | -CNY 348.87M | 48.9% | -1.43 | CNY 757.38M | CNY 422.40M | CNY 1.17B |
| FY2023 | CNY 173.86M | -CNY 768.00M | -CNY 413.00M | 50.7% | -1.87 | CNY 1.01B | CNY 318.80M | CNY 1.68B |
| FY2022 | CNY 145.70M | -CNY 846.14M | -CNY 637.31M | 40.3% | -2.06 | CNY 1.38B | CNY 279.13M | CNY 2.35B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 84.96M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is JW (Cayman) Therapeutics Co. Ltd's market cap?
JW (Cayman) Therapeutics Co. Ltd's market capitalization is EUR 84.96M.
What does JW (Cayman) Therapeutics Co. Ltd do?
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.